1. Home
  2. JAGU vs GRDX Comparison

JAGU vs GRDX Comparison

Compare JAGU & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jaguar Uranium Corp. Class A Common Shares

JAGU

Jaguar Uranium Corp. Class A Common Shares

N/A

Current Price

$1.47

Market Cap

32.3M

Sector

N/A

ML Signal

N/A

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

HOLD

Current Price

$3.60

Market Cap

28.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JAGU
GRDX
Founded
2022
N/A
Country
Canada
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.3M
28.6M
IPO Year
2025
2016

Fundamental Metrics

Financial Performance
Metric
JAGU
GRDX
Price
$1.47
$3.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 95.3K
81.9K
Earning Date
03-27-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 68.67
21.95
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.41
$1.87
52 Week High
$3.60
$6.93

Technical Indicators

Market Signals
Indicator
JAGU
GRDX
Relative Strength Index (RSI) 37.77 51.96
Support Level N/A $2.63
Resistance Level $1.76 $3.65
Average True Range (ATR) 0.11 0.34
MACD -0.01 0.08
Stochastic Oscillator 20.24 56.00

Price Performance

Historical Comparison
JAGU
GRDX

About JAGU Jaguar Uranium Corp. Class A Common Shares

Jaguar Uranium Corp is a uranium exploration and development company focused on uranium discoveries. The company is a junior miner engaged in uranium exploration. Its portfolio is comprised of two uranium exploration projects in Argentina and one uranium exploration project in Colombia. Its projects include the Berlin Project, the Laguna Project, and the Huemul Project. The company operates in one reportable segment which is the exploration and evaluation of mineral properties.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: